Biology of Blood and Marrow Transplantation最新文献

{"title":"Outcomes and Challenges of Reproductive Health in Hematopoietic Stem Cell Transplantation Survivors","authors":"Christianne Bourlon ,&nbsp;Santiago Riviello-Goya ,&nbsp;Aldo A Acosta-Medina ,&nbsp;Rosa E. Caballero-Landinez ,&nbsp;Angelica Manrique-Rubio ,&nbsp;Kevin Teran-De-la-Sancha ,&nbsp;Alfonso Gulias-Herrero ,&nbsp;Maria T. Bourlon","doi":"10.1016/j.bbmt.2020.07.007","DOIUrl":"10.1016/j.bbmt.2020.07.007","url":null,"abstract":"<div><p>Long-term therapy-related reproductive health side effects impact the quality of life of hematopoietic stem cell transplantation (HSCT) survivors. In this study, we evaluated the prevalence of gonadal dysfunction (GD) pre- and post-HSCT, analyzed factors associated with GD, and explored rates of fertility assessment (FA) and fertility preservation (FP) in a resource-limited setting. FA and outcomes of patients age ≤45 years undergoing HSCT between June 2000 and May 2018 were collected retrospectively. We included 213 patients with a median age of 26 years. Pre-HSCT FA was performed in 71.8%, with a GD rate of 17%. The rate of GD was not different between the sexes (females, 19.5% versus males, 16.1%; <em>P</em> = .616) and was only associated with increasing age. The rate of cryopreservation in the cohort was 3.3%. Almost one-half (47.7%) of post-HSCT patients completed FA and evidenced an increase in GD rate to 48.9%. Comparing pre-HSCT and post-HSCT GD rates, women had a significant increase (19.5% versus 81.4%; <em>P</em> &lt; .001), whereas men did not (16.1% versus 20.4%; <em>P</em> = .76). These results were confirmed by a multiple imputation analysis accounting for missing data. Female sex, pre-HSCT cytotoxic therapy, myeloablative conditioning, and germ cell tumor (GCT) diagnosis were associated with post-HSCT GD. Reproductive health preservation can be positively impacted when FA and FP are prioritized at the initial diagnosis in HSCT candidates, particularly in women of older age and men with a diagnosis of GCT. The low FP success observed urges implementation of strategies that favor accessibility and improve quality of life of HSCT survivors in low- and middle-income countries.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2127-2131"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38154656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients","authors":"Alpana Waghmare ,&nbsp;Maheen Z. Abidi ,&nbsp;Michael Boeckh ,&nbsp;Roy F. Chemaly ,&nbsp;Sanjeet Dadwal ,&nbsp;Zeinab El Boghdadly ,&nbsp;Mini Kamboj ,&nbsp;Genovefa A. Papanicolaou ,&nbsp;Steven A. Pergam ,&nbsp;Zainab Shahid","doi":"10.1016/j.bbmt.2020.07.027","DOIUrl":"10.1016/j.bbmt.2020.07.027","url":null,"abstract":"<div><p>There are currently limited data on the epidemiology, clinical manifestations, and optimal management of Coronavirus Disease 2019 (COVID-19) in hematopoietic cell transplantation and cellular therapy recipients. Given the experience with other respiratory viruses, we anticipate that patients may develop severe clinical disease and thus provide the following general principles for cancer centers across the nation. These guidelines were developed by members of the American Society for Transplantation and Cellular Therapy Infectious Diseases Special Interest Group. Specific practices may vary depending on local epidemiology and testing capacity, and the guidance provided in this document may change as new information becomes available.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 1983-1994"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38213319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation","authors":"Louise Bondeelle ,&nbsp;Sylvie Chevret ,&nbsp;Charlotte Hurabielle ,&nbsp;Laila Samy ,&nbsp;Tiphaine Goletto ,&nbsp;Adrien Costantini ,&nbsp;Flore Sicre de Fontbrune ,&nbsp;David Michonneau ,&nbsp;Gérard Socié ,&nbsp;Abdellatif Tazi ,&nbsp;Jean-David Bouaziz ,&nbsp;Anne Bergeron","doi":"10.1016/j.bbmt.2020.07.033","DOIUrl":"10.1016/j.bbmt.2020.07.033","url":null,"abstract":"<div><p>Ruxolitinib, a selective Janus kinase (JAK)1/2 inhibitor, has recently been proposed for steroid-refractory chronic graft-versus host disease (cGVHD) after allogeneic hematopoietic stem cell transplantation (HSCT), particularly in severe skin cGVHD. Lung function impairment is common in severe skin cGVHD through concomitant bronchiolitis obliterans syndrome (BOS) or restrictive lung disease (RLD) from skin sclerosis. To date, no treatment has shown a benefit on lung function in this context. We retrospectively assessed the effect of ruxolitinib on lung function in a cohort of 70 patients diagnosed with sclerotic-type skin cGVHD between March 2015 and April 2018. Among these patients, 36 received ruxolitinib. To handle confounding by indication bias, exposure groups were matched on the propensity score to receive ruxolitinib, incorporating age, myeloablative conditioning, total body irradiation, BOS, forced expiratory volume in 1 second (FEV₁), forced vital capacity (FVC), and tobacco use at the time of cohort entry, as well as the time from transplantation. The 1:1 matching used a greedy-matching algorithm with replacement, with a caliper of 0.10. FVC and FEV₁ trajectories during follow-up were compared in the matched samples, using linear mixed-effects models. The median duration of follow-up of the 46 matched patients was 58 months (interquartile range, 32 to 84 months). Ten patients had an RLD (6 exposed, 4 unexposed), and 13 patients were diagnosed with BOS (8 exposed, 5 unexposed). FEV₁ decreased significantly over time independent of exposure to ruxolitinib (<em>P</em> &lt; .0001). The FEV₁ trajectory was similar in the exposed patients and the unexposed patients (<em>P</em> = .11). In conclusion, ruxolitinib administration did not demonstrate any improvement in the course of respiratory function in allogeneic HSCT recipients with sclerotic-type skin cGVHD.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2115-2120"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.033","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38224692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Anti-CMV IgG Titers and CD34 Count Prior to Hematopoietic Stem Cell Transplantation from Alternative Donors on CMV reactivation","authors":"Leonardo Javier Arcuri ,&nbsp;Marcelo Schirmer ,&nbsp;Marta Colares ,&nbsp;Simone Maradei ,&nbsp;Rita Tavares ,&nbsp;Maria Claudia Rodrigues Moreira ,&nbsp;Renato de Castro Araujo ,&nbsp;Decio Lerner ,&nbsp;Antonio Guilherme Fonseca Pacheco","doi":"10.1016/j.bbmt.2020.07.034","DOIUrl":"10.1016/j.bbmt.2020.07.034","url":null,"abstract":"<div><p>Cytomegalovirus (CMV) reactivation remains one of the main infectious complications following hematopoietic stem cell transplantation (HSCT). In this study, we explored the role of anti-CMV antibody titers in HSCT from alternative donors and to compare the risk of CMV reactivation between posttransplant cyclophosphamide-based haploidentical HSCT and antithymocyte globulin-based unrelated donor (URD) HSCT. We included 98 CMV-positive patients, 30 undergoing haploidentical HSCT and 68 undergoing URD HSCT. The majority of patients had a malignant disease (84%), received a myeloablative conditioning regimen (78%), and received a bone marrow graft (90%). The median pretransplantation anti-CMV IgG level was 109 U/mL. With median follow-up of 2.2 years, a total of 72 CMV reactivations occurred in 50 patients. There was no difference in CMV reactivation pattern between haploidentical HSCT recipients and URD HSCT recipients. In multivariable analysis until the first event, the incidence of CMV reactivation was higher in patients with anti-CMV IgG levels &gt;100 U/mL (hazard ratio [HR], 2.38; <em>P</em> = .005) and in patients diagnosed with grade II-IV acute graft-versus-host disease (GVHD) (HR, 10.8; <em>P</em> = .003) after day +50 and lower in patients who received higher doses of CD34 cells (HR, .44; <em>P</em> = .006). In multivariable analysis for recurring events, the incidence of CMV reactivation was higher in patients receiving reduced-intensity conditioning (HR, 1.69: <em>P</em> = .04) and in patients with acute GVHD (HR, 1.88; <em>P</em> = .02), and lower in those who received higher doses of CD34 cells (HR, .55; <em>P</em> = .01). In summary, we have shown that pretransplantation anti-CMV IgG titers are correlated with CMV reactivation risk. More studies are needed to assess how this information can be incorporated in HSCT. The use of high-dose cellular grafts, a modifiable risk factor, also protects against CMV reactivation.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages e275-e279"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38225932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Officers and Directors of ASTCT","authors":"","doi":"10.1016/S1083-8791(20)30635-2","DOIUrl":"https://doi.org/10.1016/S1083-8791(20)30635-2","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Page A7"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1083-8791(20)30635-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137415556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HLA-Matched Unrelated Donors for Patients with Sickle Cell Disease: Results of International Donor Searches","authors":"Karina Tozatto-Maio ,&nbsp;Margareth Afonso Torres ,&nbsp;Neifi Hassan Saloum Degaide ,&nbsp;Juliana Fernandes Cardoso ,&nbsp;Fernanda Volt ,&nbsp;Ana Cristina Silva Pinto ,&nbsp;Danielli Oliveira ,&nbsp;Hanadi Elayoubi ,&nbsp;Simone Kashima ,&nbsp;Pascale Loiseau ,&nbsp;Hendrik Veelken ,&nbsp;Alina Ferster ,&nbsp;Barbara Cappelli ,&nbsp;Evandra Strazza Rodrigues ,&nbsp;Graziana Maria Scigliuolo ,&nbsp;Chantal Kenzey ,&nbsp;Annalisa Ruggeri ,&nbsp;Vanderson Rocha ,&nbsp;Belinda Pinto Simões ,&nbsp;Ryad Tamouza ,&nbsp;Eliane Gluckman","doi":"10.1016/j.bbmt.2020.07.015","DOIUrl":"10.1016/j.bbmt.2020.07.015","url":null,"abstract":"<div><p>Sickle cell disease (SCD) is the most common inherited hemoglobinopathy. Hematopoietic stem cell transplantation (HCT) is the sole curative therapy for SCD, but few patients will have a matched sibling donor. Patients with SCD are mostly of African origin and thus are less likely to find a matched unrelated donor in international registries. Using HaploStats, we estimated HLA haplotypes for 185 patients with SCD (116 from a Brazilian center and 69 from European Society for Blood and Marrow Transplantation [EBMT] centers) and classified the ethnic origin of haplotypes. Then we assessed the probability of finding an HLA-matched unrelated adult donor (MUD), considering loci A, B, and DRB1 (6/6), in international registries. Most haplotypes were African, but Brazilians showed a greater ethnic admixture than EBMT patients. Nevertheless, the chance of finding at least one 6/6 potential allelic donor was 47% for both groups. Most potential allelic donors were from the US National Marrow Donor Program registry and from the Brazilian REDOME donor registry. Although the probability of finding a donor is higher than previously reported, strategies are needed to improve ethnic diversity in registries. Moreover, predicting the likelihood of having an MUD might influence SCD management.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2034-2039"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.015","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38195359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome","authors":"Polona Novak ,&nbsp;Tatjana Zabelina ,&nbsp;Christine Wolschke ,&nbsp;Francis Ayuk ,&nbsp;Maximilian Christopeit ,&nbsp;Nicolaus Kröger","doi":"10.1016/j.bbmt.2020.07.018","DOIUrl":"10.1016/j.bbmt.2020.07.018","url":null,"abstract":"<div><p>The indication for allogeneic stem cell transplantation (SCT) in patients with lower-risk myelodysplastic syndrome (MDS) is controversial. Here we report 60 patients with a low risk (n = 32) or intermediate risk (n = 28) classification according to the revised International Prognostic Scoring System (IPSS-R) who underwent allogeneic SCT with a reduced-intensity conditioning (n = 45) or myeloablative conditioning (n = 15) regimen from an HLA-identical sibling (n = 9), a matched unrelated donor (n = 36), or a mismatched unrelated donor (n = 15). The rates of grade II-IV and grade III-IV acute graft-versus-host disease were 32% and 7%, respectively, resulting in a transplantation-related mortality (TRM) of 17% at 3 years. The cumulative incidence of relapse at 5 years was only 7%, resulting in a 5-year disease-free survival of 72% and overall survival (OS) of 79%. Transplantation from a fully matched donor resulted in significantly improved OS at 5 years (91% versus 70%). Allogeneic SCT in lower-risk MDS (IPSS-R low or intermediate risk) from an HLA-matched donor resulted in excellent OS with a low risk of relapse.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2047-2052"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38205687","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chimeric Antigen Receptor T Cell Therapy in Patients with Multiply Relapsed or Refractory Extramedullary Leukemia","authors":"Jeremy D. Rubinstein ,&nbsp;Christa Krupski ,&nbsp;Adam S. Nelson ,&nbsp;Maureen M. O'Brien ,&nbsp;Stella M. Davies ,&nbsp;Christine L. Phillips","doi":"10.1016/j.bbmt.2020.07.036","DOIUrl":"10.1016/j.bbmt.2020.07.036","url":null,"abstract":"<div><p>Autologous CD19-directed chimeric antigen receptor T lymphocyte (CAR-T) therapy is an approved and effective treatment for the management of patients with refractory and multiply relapsed B cell precursor acute lymphoblastic leukemia (B-ALL). Experience using this therapy in pediatric patients with extramedullary (EM) disease is limited, in part because these patients have frequently been excluded from clinical trials owing to concerns for an increased risk of immune effector cell-associated neurotoxicity syndrome (ICANS). We infused 7 patients with refractory or multiply relapsed B-ALL who presented with isolated EM relapse with tisagenlecleucel. Six patients had isolated central nervous system (CNS) leukemia, and 1 patient had an isolated testicular relapse. An initial complete response was seen in all patients, with 5 patients remaining in CAR-T-induced remission at a median of 18 months from first infusion. Reversible ICANS was seen in 1 patient with CNS leukemia. Durable B cell aplasia occurred in 3 patients, with a median time to B cell recovery of 6.5 months in the other patients. These data suggest that CAR-T therapy has promising safety and efficacy in treating EM leukemia, although definitive conclusions are limited by the small size of the cohort and limited follow-up period.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages e280-e285"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.07.036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38231957","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia","authors":"Kotaro Miyao ,&nbsp;Seitaro Terakura ,&nbsp;Fumihiko Kimura ,&nbsp;Takaaki Konuma ,&nbsp;Koichi Miyamura ,&nbsp;Masamitsu Yanada ,&nbsp;Shinichi Kako ,&nbsp;Satoko Morhishima ,&nbsp;Naoyuki Uchida ,&nbsp;Takashi Toya ,&nbsp;Yukiyasu Ozawa ,&nbsp;Takahiro Fukuda ,&nbsp;Masatsugu Tanaka ,&nbsp;Masashi Sawa ,&nbsp;Satoru Takada ,&nbsp;Shuro Yoshida ,&nbsp;Takafumi Kimura ,&nbsp;Tatsuo Ichinohe ,&nbsp;Yoshiko Atsuta ,&nbsp;Junya Kanda","doi":"10.1016/j.bbmt.2020.08.001","DOIUrl":"10.1016/j.bbmt.2020.08.001","url":null,"abstract":"<div><p>The outcomes of 7/8 allele-matched unrelated bone marrow transplantation (7/8 UBMT) and umbilical cord blood transplantation (UCBT) have been improving. We retrospectively analyzed adults with acute leukemia who underwent their first 7/8 UBMT or UCBT in Japan. Between January 2008 and December 2017, a total of 4150 patients were recorded, including 488 who underwent 7/8 UBMT and 3662 who underwent UCBT. Only 32 patients with 7/8 UBMT had graft-versus-host-disease (GVHD) high-risk HLA mismatched pairs. Overall survival at 3 years was 54% for 7/8 the UBMT group and 46% for the UCBT group, a nonsignificant difference in multivariate analysis (hazard ratio [HR], 1.01; 95% confidence interval [CI], .88 to 1.17; <em>P</em> = .89). The 7/8 UBMT and UCBT groups showed a similar nonrelapse mortality rate (HR, 1.16; 95% CI, .96 to 1.45; <em>P</em> = .16) and relapse rate (HR, .85; 95% CI, .71 to 1.02; <em>P</em> = .08). However, the UCBT group had a lower risk of grade II-IV acute GVHD (HR, .76; 95% CI, .65 to .88; <em>P</em> &lt; .001) and chronic GVHD (HR, .77; 95% CI, .66- .91; <em>P</em> = .002) compared with the 7/8 UBMT group. In stratified analyses combining disease risk with conditioning intensity, 7/8 UBMT showed superior overall survival to UCBT in standard risk and myeloablative conditioning (HR, .72; 95% CI, .56 to .93; <em>P</em> = .014). Both 7/8 UBMT and UCBT are appropriate alternative donor procedures. The stem cell source can be selected on the basis of disease risk, patient tolerability, or concerns regarding GVHD.</p></div>","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 11","pages":"Pages 2105-2114"},"PeriodicalIF":4.3,"publicationDate":"2020-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.08.001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38253488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ASTCT Notes","authors":"","doi":"10.1016/j.bbmt.2020.09.002","DOIUrl":"10.1016/j.bbmt.2020.09.002","url":null,"abstract":"","PeriodicalId":9165,"journal":{"name":"Biology of Blood and Marrow Transplantation","volume":"26 10","pages":"Pages 1980-1981"},"PeriodicalIF":4.3,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbmt.2020.09.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"25510023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}